The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials…
Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults…
The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…
A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions…
PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose…
Ciltacabtagene autoleucel, an investigational CAR T-cell therapy for multiple myeloma, continues to lead to deep and durable responses in heavily treated patients with relapsed or…
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple…
Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company…
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among…
